These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Lessons From ADAURA on Adjuvant Cancer Drug Trials: Evidence, Ethics, and Economics. Gyawali B; West HJ J Clin Oncol; 2021 Jan; 39(3):175-177. PubMed ID: 33275490 [No Abstract] [Full Text] [Related]
34. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
35. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Hochmair MJ; Morabito A; Hao D; Yang CT; Soo RA; Yang JC; Gucalp R; Halmos B; Wang L; Golembesky A; Märten A; Cufer T Future Oncol; 2018 Nov; 14(27):2861-2874. PubMed ID: 30336693 [TBL] [Abstract][Full Text] [Related]
36. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328 [TBL] [Abstract][Full Text] [Related]
37. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. Jenkins S; Yang JC; Jänne PA; Thress KS; Yu K; Hodge R; Weston S; Dearden S; Patel S; Cantarini M; Shepherd FA J Thorac Oncol; 2017 Aug; 12(8):1247-1256. PubMed ID: 28527899 [TBL] [Abstract][Full Text] [Related]
38. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Mann H; Andersohn F; Bodnar C; Mitsudomi T; Mok TSK; Yang JC; Hoyle C Clin Drug Investig; 2018 Apr; 38(4):319-331. PubMed ID: 29247383 [TBL] [Abstract][Full Text] [Related]
39. Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer. Ricciuti B; Chiari R; Chiarini P; Crinò L; Maiettini D; Ludovini V; Metro G Clin Drug Investig; 2016 Aug; 36(8):683-6. PubMed ID: 27177916 [TBL] [Abstract][Full Text] [Related]